LIVIVO - Search results -

Search results

Result 1 - 10 of total 39

Search options

Article ; Online: Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment.

Minatoguchi, Shun / Hayashi, Hiroki / Umeda, Ryosuke / Koide, Shigehisa / Hasegawa, Midori / Tsuboi, Naotake

2024

Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney disease (ESKD). Vasopressin plays a pivotal role in ADPKD progression; therefore, the selective vasopressin V2 receptor antagonist tolvaptan is used as a key drug ... ...

Abstract	Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney disease (ESKD). Vasopressin plays a pivotal role in ADPKD progression; therefore, the selective vasopressin V2 receptor antagonist tolvaptan is used as a key drug in the management of ADPKD. On the other hand, sodium-glucose cotransporter-2 inhibitors (SGLT2i), which may possibly stimulate vasopressin secretion due to the diuretic effect of the drug, have been shown to have both renal and cardioprotective effects in various populations, including those with non-diabetic chronic kidney disease. However, the effect of SGLT2i in patients with ADPKD have not been fully elucidated. Herein, we report the case of a patient with ADPKD on tolvaptan who was administered the SGLT2i dapagliflozin. The patient was a Japanese woman diagnosed with ADPKD at age 30. Despite the treatment with tolvaptan, eGFR was gradually declined from 79.8 to 50 ml/min/1.73 m
Language	English
Publishing date	2024-03-18
Publishing country	Japan
Document type	Journal Article
ZDB-ID	2660492-9
ISSN	2192-4449 ; 2192-4449
ISSN (online)	2192-4449
ISSN	2192-4449
DOI	10.1007/s13730-024-00859-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article ; Online: Tolvaptan's Association with Low Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease and Acute Decompensated Heart Failure.

Tagaya, Tomoki / Hayashi, Hiroki / Ogata, Soshiro / Takahashi, Kazuo / Koide, Shigehisa / Inaguma, Daijo / Hasegawa, Midori / Yuzawa, Yukio / Tsuboi, Naotake

American journal of nephrology

2023 Volume 54, Issue 7-8, Page(s) 319–328

Abstract: Introduction: Furosemide, a loop diuretic, is often empirically used to treat acute decompensated heart failure (ADHF) initially. Conversely, decongestion using tolvaptan, an aquaretic, is thought to maintain renal function compared to furosemide. ... ...

Abstract	Introduction: Furosemide, a loop diuretic, is often empirically used to treat acute decompensated heart failure (ADHF) initially. Conversely, decongestion using tolvaptan, an aquaretic, is thought to maintain renal function compared to furosemide. However, it has not been investigated in patients with advanced chronic kidney disease (CKD) at high risk of developing acute kidney injury (AKI). This study aimed to investigate AKI incidence using tolvaptan add-on treatment, compared to increased furosemide treatment for patients with ADHF complicated by advanced CKD. Methods: We retrospectively studied patients with advanced CKD (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m2) who developed ADHF under outpatient furosemide treatment. The exposure was set to tolvaptan add-on treatment, and the control was set to increased furosemide treatment. Results: Of the 163 patients enrolled, 79 were in the tolvaptan group and 84 in the furosemide group. The mean age was 71.6 years, the percentage of males was 63.8%, the mean eGFR was 15.7 mL/min/1.73 m2, and patients with CKD stage G5 were 61.9%. AKI incidence was 17.7% in the tolvaptan group and 42.9% in the furosemide group (odds ratio [95% confidence interval]: 0.34 [0.13-0.86], p = 0.023 in multivariate logistic regression analysis). Persistent AKI incidence was 11.8% in the tolvaptan group and 32.9% in the furosemide group (odds ratio [95% confidence interval]: 0.34 [0.10-1.06], p = 0.066 in the multinomial logit analysis). Conclusion: This study suggests that tolvaptan may be better than furosemide in patients with ADHF experiencing complicated advanced CKD.
MeSH term(s)	Male ; Humans ; Aged ; Tolvaptan/adverse effects ; Furosemide/adverse effects ; Antidiuretic Hormone Receptor Antagonists/adverse effects ; Retrospective Studies ; Benzazepines ; Heart Failure/complications ; Heart Failure/drug therapy ; Heart Failure/epidemiology ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/epidemiology ; Renal Insufficiency, Chronic/chemically induced ; Acute Kidney Injury/etiology ; Acute Kidney Injury/chemically induced ; Acute Disease
Chemical Substances	Tolvaptan (21G72T1950) ; Furosemide (7LXU5N7ZO5) ; Antidiuretic Hormone Receptor Antagonists ; Benzazepines
Language	English
Publishing date	2023-06-29
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	604540-6
ISSN	1421-9670 ; 0250-8095
ISSN (online)	1421-9670
ISSN	0250-8095
DOI	10.1159/000531692
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1635: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.

Kimura, Wakana / Minatoguchi, Shun / Mizuno, Tomohiro / Koide, Shigehisa / Hayashi, Hiroki / Hasegawa, Midori / Inaguma, Daijo / Tsuboi, Naotake

Journal of nephrology

2023 Volume 37, Issue 1, Page(s) 171–179

Abstract: Background: Sodium zirconium cyclosilicate, a non-absorbed non-polymer zirconium silicate, is a new potassium binder for hyperkalemia. A previous report showed that administering sodium zirconium cyclosilicate to patients with hyperkalemia allows a ... ...

Abstract	Background: Sodium zirconium cyclosilicate, a non-absorbed non-polymer zirconium silicate, is a new potassium binder for hyperkalemia. A previous report showed that administering sodium zirconium cyclosilicate to patients with hyperkalemia allows a higher continuation rate of renin-angiotensin-aldosterone system inhibitors. However, no studies have compared sodium zirconium cyclosilicate with existing potassium binders for renin-angiotensin-aldosterone system inhibitor continuity. The purpose of this study was to evaluate the effect of sodium zirconium cyclosilicate on angiotensin-converting enzyme inhibitor /angiotensin receptor blocker continuation in patients with hyperkalemia compared to that of calcium polystyrene sulfonate. Methods: Patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers who were newly prescribed sodium zirconium cyclosilicate or calcium polystyrene sulfonate to treat hyperkalemia at a tertiary referral hospital between August 2020 and April 2022 were enrolled in this single-center, retrospective observational study. The primary outcome measure was angiotensin-converting enzyme inhibitor/angiotensin receptor blocker prescription three months after initiating potassium binders. Results: In total, 174 patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers who were newly administered sodium zirconium cyclosilicate (n = 62) or calcium polystyrene sulfonate (n = 112) were analyzed. The prescription rate of angiotensin-converting enzyme inhibitors /angiotensin receptor blockers at 3 months was significantly higher in the sodium zirconium cyclosilicate group than in the calcium polystyrene sulfonate group (89 vs. 72%). Multivariate logistic regression models showed that sodium zirconium cyclosilicate was independently associated with the primary outcome (odds ratio 2.66, 95% confidence interval 1.05-7.43). The propensity score-matched comparison also showed a significant association between sodium zirconium cyclosilicate and the primary outcome. Conclusions: Our study suggests that administering sodium zirconium cyclosilicate to patients with hyperkalemia allows for a higher continuation rate of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers than calcium polystyrene sulfonate. These findings suggest that sodium zirconium cyclosilicate has potential benefits for patients with chronic kidney disease receiving renin-angiotensin-aldosterone system inhibitors.
MeSH term(s)	Humans ; Hyperkalemia/diagnosis ; Hyperkalemia/drug therapy ; Renin-Angiotensin System ; Potassium ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Polymers/pharmacology ; Renal Insufficiency, Chronic ; Antihypertensive Agents ; Angiotensin Receptor Antagonists/adverse effects ; Polystyrenes ; Silicates
Chemical Substances	polystyrene sulfonic acid (70KO0R01RY) ; sodium zirconium cyclosilicate (D652ZWF066) ; Potassium (RWP5GA015D) ; Angiotensin-Converting Enzyme Inhibitors ; Polymers ; Antihypertensive Agents ; Angiotensin Receptor Antagonists ; Polystyrenes ; Silicates
Language	English
Publishing date	2023-08-22
Publishing country	Italy
Document type	Observational Study ; Journal Article
ZDB-ID	1093991-x
ISSN	1724-6059 ; 1120-3625 ; 1121-8428
ISSN (online)	1724-6059
ISSN	1120-3625 ; 1121-8428
DOI	10.1007/s40620-023-01743-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3369: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Comparison of the Serial Humoral Immune Response according to the Immunosuppressive Treatment after SARS-CoV-2 mRNA Vaccination.

Menjo, Hiroya / Hasegawa, Midori / Fujigaki, Hidetsugu / Ishihara, Takuma / Minatoguchi, Shun / Koide, Shigehisa / Hayashi, Hiroki / Saito, Midori / Takahashi, Kazuo / Ito, Hiroyasu / Yuzawa, Yukio / Saito, Kuniaki / Tsuboi, Naotake

Internal medicine (Tokyo, Japan)

2023 Volume 62, Issue 23, Page(s) 3445–3454

Abstract: Objective The objective of this study was to estimate the humoral immune response evaluated by immunoglobulin G (IgG) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD-IgG) following the third ... ...

Abstract	Objective The objective of this study was to estimate the humoral immune response evaluated by immunoglobulin G (IgG) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD-IgG) following the third mRNA coronavirus disease 2019 (COVID-19) vaccination in patients with kidney disease who received immunosuppressive treatment. Methods The primary outcome was RBD-IgG levels after the third SARS-CoV-2 vaccination. The primary comparison was the RBD-IgG levels between patients with kidney disease who received immunosuppressive treatment (n=124) and those who did not (n=33). Results The RBD-IgG levels were significantly lower in the patients with kidney disease who received immunosuppressive treatment than in those who did not receive immunosuppressive treatment. The RBD-IgG levels were lower in patients treated with glucocorticoid monotherapy than in those who did not receive immunosuppressive treatment. Even in patients who received ≤5 mg prednisolone, the RBD-IgG levels were significantly lower. Nine of the 10 patients who received rituximab within one year before the first vaccination did not experience seroconversion after the third vaccination. Meanwhile, all nine patients who received rituximab only after the second vaccination experienced seroconversion, even if B cell recovery was insufficient. Patients treated with mycophenolate mofetil plus glucocorticoid plus belimumab had significantly lower RBD-IgG levels than those treated with mycophenolate mofetil plus glucocorticoid. Conclusion The RBD-IgG levels were lower in patients with kidney disease who received immunosuppressive treatment than in those who did not receive immunosuppressive treatment. Low-dose glucocorticoid monotherapy affected the humoral immune response following the third mRNA COVID-19 vaccination.
MeSH term(s)	Humans ; Immunity, Humoral ; Rituximab ; COVID-19 Vaccines ; SARS-CoV-2 ; Mycophenolic Acid ; Glucocorticoids/therapeutic use ; COVID-19/prevention & control ; Immunosuppressive Agents/therapeutic use ; Immunoglobulin G ; RNA, Messenger ; Vaccination ; Kidney Diseases ; Antibodies, Viral
Chemical Substances	Rituximab (4F4X42SYQ6) ; COVID-19 Vaccines ; Mycophenolic Acid (HU9DX48N0T) ; Glucocorticoids ; Immunosuppressive Agents ; Immunoglobulin G ; RNA, Messenger ; Antibodies, Viral
Language	English
Publishing date	2023-09-29
Publishing country	Japan
Document type	Journal Article
ZDB-ID	32371-8
ISSN	1349-7235 ; 0021-5120 ; 0918-2918
ISSN (online)	1349-7235
ISSN	0021-5120 ; 0918-2918
DOI	10.2169/internalmedicine.1949-23
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Relationship between selection of dosage forms of vitamin D receptor activators and short-term survival of patients on hemodialysis.

Koshi-Ito, Eri / Inaguma, Daijo / Koide, Shigehisa / Takahashi, Kazuo / Hayashi, Hiroki / Tsuboi, Naotake / Hasegawa, Midori / Maruyama, Shoichi / Yuzawa, Yukio

Renal failure

2021 Volume 43, Issue 1, Page(s) 1528–1538

Abstract: Background: The benefits of vitamin D receptor activators (VDRAs) for patients with chronic kidney disease are well recognized. However, the optimal criteria for patient selection, dosage forms, and duration providing the highest benefit and the least ... ...

Abstract	Background: The benefits of vitamin D receptor activators (VDRAs) for patients with chronic kidney disease are well recognized. However, the optimal criteria for patient selection, dosage forms, and duration providing the highest benefit and the least potential risk remain to be confirmed. Materials and methods: The study population was derived from the Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis, a multicenter prospective cohort study of 1520 incident dialysis patients. According to the VDRA usage status in March 2015 (interim report), the 967 patients surviving after March 2015 were classified into three groups: without VDRA (NV, Results: There were 104 deaths (NV, Conclusion: This study demonstrated the impact of the VDRA dosage form on the short-term survival of incident hemodialysis patients during the introduction period. Our results suggest that relatively early initiation of intravenous VDRA in patients beginning hemodialysis may have some clinical potential.
MeSH term(s)	Administration, Intravenous ; Administration, Oral ; Aged ; Cause of Death ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Japan ; Male ; Middle Aged ; Prospective Studies ; Receptors, Calcitriol/administration & dosage ; Renal Dialysis/methods ; Renal Insufficiency, Chronic/drug therapy ; Renal Insufficiency, Chronic/mortality ; Renal Insufficiency, Chronic/therapy ; Risk Factors ; Survival Analysis ; Time Factors ; Treatment Outcome
Chemical Substances	Receptors, Calcitriol
Language	English
Publishing date	2021-10-11
Publishing country	England
Document type	Journal Article ; Multicenter Study
ZDB-ID	632949-4
ISSN	1525-6049 ; 0886-022X
ISSN (online)	1525-6049
ISSN	0886-022X
DOI	10.1080/0886022X.2021.1995423
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1331: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Combination of brain natriuretic peptide and urinary albumin as a predictor of cardiovascular-renal events in outpatients with chronic kidney disease.

Oyama, Shoya / Takahashi, Hiroshi / Hayashi, Hiroki / Koide, Shigehisa / Nakai, Shigeru / Takahashi, Kazuo / Inaguma, Daijo / Hasegawa, Midori / Ishii, Junichi / Yuzawa, Yukio / Tsuboi, Naotake

Fujita medical journal

2022 Volume 9, Issue 2, Page(s) 105–112

Abstract: Objectives: Cardiovascular and renal diseases are closely related. Brain natriuretic peptide (BNP) and urinary albumin are established predictors for cardiac and renal morbidities, respectively. To date, no reports have investigated the combined ... ...

Abstract	Objectives: Cardiovascular and renal diseases are closely related. Brain natriuretic peptide (BNP) and urinary albumin are established predictors for cardiac and renal morbidities, respectively. To date, no reports have investigated the combined predictive value of BNP and urinary albumin for long-term cardiovascular-renal events in patients with chronic kidney disease (CKD). The aim of this study was to investigate this theme. Methods: Four hundred eighty-three patients with CKD were enrolled into this study and followed-up for 10 years. The endpoint was cardiovascular-renal events. Results: During the median follow-up period of 109 months, 221 patients developed cardiovascular-renal events. Log-transformed BNP and urinary albumin were identified as independent predictors for cardiovascular-renal events, with a hazard ratio of 2.59 (95% confidence interval [CI], 1.81-3.72) and 2.27 (95% CI, 1.82-2.84) for BNP and urinary albumin, respectively. For the combined variables, the group with high BNP and urinary albumin had a markedly higher risk (12.41-times; 95% CI 5.23-29.42) of cardiovascular-renal events compared with that of the group with low BNP and urinary albumin. Adding both variables to a predictive model with basic risk factors improved the C-index (0.767, 0.728 to 0.814, p=0.009), net reclassification improvement (0.497, p<0.0001), and integrated discrimination improvement (0.071, p<0.0001) more than each of them alone. Conclusions: This is the first report to demonstrate that the combination of BNP and urinary albumin can stratify and improve the predictability of long-term cardiovascular-renal events in CKD patients.
Language	English
Publishing date	2022-07-22
Publishing country	Japan
Document type	Journal Article
ZDB-ID	3011241-2
ISSN	2189-7255 ; 2189-7247
ISSN (online)	2189-7255
ISSN	2189-7247
DOI	10.20407/fmj.2022-004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function.

Hasegawa, Midori / Kitaguchi, Nobuya / Takechi, Hajime / Kawaguchi, Kazunori / Ito, Kengo / Kato, Takashi / Kato, Masao / Nii, Norio / Yamada, Sachie / Ohashi, Atsushi / Koide, Shigehisa / Hayashi, Hiroki / Takahashi, Kazuo / Inaguma, Daijo / Yuzawa, Yukio / Tsuboi, Naotake

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

2022 Volume 26, Issue 3, Page(s) 529–536

Abstract: Introduction: Amyloid β (Aβ) is a brain protein that causes Alzheimer's disease (AD). This study aimed to verify whether hemadsorption using a hexadecyl-alkylated cellulose bead (HexDC) column removes blood Aβ and brain Aβ accumulation in mild cognitive ...

Abstract	Introduction: Amyloid β (Aβ) is a brain protein that causes Alzheimer's disease (AD). This study aimed to verify whether hemadsorption using a hexadecyl-alkylated cellulose bead (HexDC) column removes blood Aβ and brain Aβ accumulation in mild cognitive impairment/mild AD cases with normal kidney function. Methods: Two patients with positive Aβ on brain imaging underwent HexDC hemadsorption weekly for 6 months. Results: The Aβ removal efficiency of HexDC was 87-99%. Aβ Conclusion: Blood Aβ removal was performed in two early AD patients with normal kidney function without adverse events, and it slightly improved or maintained cognitive function.
MeSH term(s)	Alzheimer Disease/metabolism ; Alzheimer Disease/therapy ; Amyloid beta-Peptides/metabolism ; Brain ; Cognitive Dysfunction/etiology ; Humans ; Kidney/metabolism
Chemical Substances	Amyloid beta-Peptides
Language	English
Publishing date	2022-03-21
Publishing country	Australia
Document type	Journal Article
ZDB-ID	2119809-3
ISSN	1744-9987 ; 1091-6660 ; 1744-9979
ISSN (online)	1744-9987
ISSN	1091-6660 ; 1744-9979
DOI	10.1111/1744-9987.13827
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5208: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Impact of high mortality in incident dialysis patients due to hypertensive nephrosclerosis: a multicenter prospective cohort study in Aichi, Japan.

Inaguma, Daijo / Ito, Eri / Takahashi, Kazuo / Hayashi, Hiroki / Koide, Shigehisa / Hasegawa, Midori / Yuzawa, Yukio

Clinical and experimental nephrology

2018 Volume 22, Issue 6, Page(s) 1360–1370

Abstract: Introduction: An increasing number of patients worldwide require dialysis as a result of hypertensive nephrosclerosis (HTN). However, in Japan, mortality in patients with end-stage renal disease (ESRD) has not been well by primary kidney disease ... ...

Abstract	Introduction: An increasing number of patients worldwide require dialysis as a result of hypertensive nephrosclerosis (HTN). However, in Japan, mortality in patients with end-stage renal disease (ESRD) has not been well by primary kidney disease including HTN and diabetic nephropathy (DN). Hence, we examined the differences in mortality among the primary kidney diseases of incident dialysis patients. Methods: The study was a multicenter prospective cohort analysis including 1520 incident dialysis patients in Aichi prefecture, Japan. We classified patients into three groups according to the primary kidney disease [i.e., a HTN group, n = 384, a DN group n = 658, and a chronic glomerulonephritis (CGN) group, n = 224]. In addition, we classified patients into the HTN group and the DN group using propensity score matching. We compared outcomes including all-cause and infection-related mortality. Results: The mortality rates of the HTN, the DN, and the CGN group, were 135.9, 64.2, and 34.8 per 1000 patient years, respectively. All-cause mortality and infection-related mortality rates in the HTN group were as high as those in the DN group after adjustment for age, gender, history of cardiovascular disease, and estimated glomerular filtration rate. No significant difference of all-cause mortality was observed after propensity score matching between the two groups (Logrank test: p = 0.523). Conclusions: The present study was Japan's first large-scale prospective cohort to demonstrate that HTN is the second most common cause of ESRD. In addition, the prognosis of patients with HTN was as poor as that of patients with DN.
MeSH term(s)	Aged ; Aged, 80 and over ; Cause of Death ; Diabetic Nephropathies/complications ; Female ; Glomerulonephritis/complications ; Humans ; Hypertension/complications ; Japan/epidemiology ; Kidney Failure, Chronic/etiology ; Kidney Failure, Chronic/mortality ; Kidney Failure, Chronic/therapy ; Male ; Middle Aged ; Nephrosclerosis/complications ; Propensity Score ; Prospective Studies ; Renal Dialysis
Language	English
Publishing date	2018-06-07
Publishing country	Japan
Document type	Journal Article ; Multicenter Study
ZDB-ID	1338768-6
ISSN	1437-7799 ; 1342-1751
ISSN (online)	1437-7799
ISSN	1342-1751
DOI	10.1007/s10157-018-1592-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4922: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method.

Ito, Eri / Inaguma, Daijo / Koide, Shigehisa / Takahashi, Kazuo / Hayashi, Hiroki / Hasegawa, Midori / Yuzawa, Yukio

Clinical and experimental nephrology

2018 Volume 22, Issue 6, Page(s) 1309–1314

Abstract: Background: Whether vitamin D receptor activator (VDRA) use is beneficial in chronic kidney disease (CKD) is unclear, because it is possible that VDRA increases serum fibroblast growth factor 23 (FGF23) levels. We will conduct a randomized controlled ... ...

Abstract	Background: Whether vitamin D receptor activator (VDRA) use is beneficial in chronic kidney disease (CKD) is unclear, because it is possible that VDRA increases serum fibroblast growth factor 23 (FGF23) levels. We will conduct a randomized controlled trial in predialysis patients to determine the effect of VDRA alone or in combination with lanthanum carbonate (LC) on serum FGF23 levels. Methods: This is a single-center, open-label, randomized controlled trial. Enrollment will commence February 1, 2018, using the following inclusion criteria: (1) age ≥ 20 years, (2) CKD with an estimated glomerular filtration rate of 10-45 mL/min/1.73 m Discussion: This study aims to determine whether low-dose oral VDRA increases serum FGF23 level and whether the combination of VDRA and LC inhibits this increase. The results will be useful in the management of CKD-mineral and bone disorder in predialysis patients. Trial registration: UMIN000030503. Registered 20 January 2018.
MeSH term(s)	Fibroblast Growth Factors/blood ; Humans ; Hydroxycholecalciferols/pharmacology ; Lanthanum/pharmacology ; Receptors, Calcitriol/physiology ; Renal Dialysis ; Renal Insufficiency, Chronic/therapy ; Research Design
Chemical Substances	Hydroxycholecalciferols ; Receptors, Calcitriol ; lanthanum carbonate (490D9F069T) ; Fibroblast Growth Factors (62031-54-3) ; Lanthanum (6I3K30563S) ; fibroblast growth factor 23 (7Q7P4S7RRE) ; alfacalcidol (URQ2517572)
Language	English
Publishing date	2018-05-10
Publishing country	Japan
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	1338768-6
ISSN	1437-7799 ; 1342-1751
ISSN (online)	1437-7799
ISSN	1342-1751
DOI	10.1007/s10157-018-1584-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4922: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Development of aortic valve stenosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement.

Hasegawa, Midori / Iwasaki, Jin / Sugiyama, Satoshi / Ishihara, Takuma / Yamamoto, Yoshihiro / Asada, Hiroaki / Koide, Shigehisa / Hayashi, Hiroki / Takahashi, Kazuo / Inaguma, Daijo / Yuzawa, Yukio / Tsuboi, Naotake

PloS one

2021 Volume 16, Issue 1, Page(s) e0245869

Abstract: Introduction: Degenerative aortic valve stenosis (AS) is a chronic progressive disease that resembles atherosclerosis development. Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is reportedly associated with accelerated atherosclerosis. ...

Abstract	Introduction: Degenerative aortic valve stenosis (AS) is a chronic progressive disease that resembles atherosclerosis development. Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is reportedly associated with accelerated atherosclerosis. This study aimed to examine the development of AS in patients with myeloperoxidase-AAV (MPO-AAV) with renal involvement at more than 1 year after the onset of vasculitis. Methods: We performed a retrospective review of clinical records of MPO-AAV patients with renal involvement without AS at the onset of vasculitis who were treated in three hospitals and three dialysis clinics. Results: The study included 97 MPO-AAV patients with renal involvement and 230 control patients with chronic kidney disease (CKD). Among them, 64 patients had AS. The prevalence rates of AS were 28.9% and 15.7% in MPO-AAV and control patients, respectively (p = 0.006). The multivariable logistic regression analysis showed that MPO-AAV, dialysis dependence, and hypertension were independently associated factors for AS. In MPO-AAV patients, systolic blood pressure was positively significantly associated with AS, whereas glucocorticoid dose of induction therapy was negatively significantly associated. The use of cyclophosphamide tended to be negatively associated with AS. The survival rate was significantly lower for patients with AS than for those without AS. Conclusions: The AS prevalence rate was significantly higher in MPO-AAV patients at more than 1 year after the onset of vasculitis than in control CKD patients. Therefore, regular monitoring of echocardiography during MPO-AAV treatment is suggested.
MeSH term(s)	Aged ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/enzymology ; Aortic Valve Stenosis/complications ; Female ; Humans ; Kidney/pathology ; Male ; Peroxidase/metabolism ; Retrospective Studies ; Survival Analysis
Chemical Substances	Peroxidase (EC 1.11.1.7)
Language	English
Publishing date	2021-01-22
Publishing country	United States
Document type	Journal Article
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0245869
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED